Seroprevalence study of COVID-19 in Saint Petersburg, Russia is a regional longitudinal cohort study aiming to evaluate the spread dynamics of the COVID-19 disease in the population of Saint Petersburg. Clinically asymptomatic adults are sampled from the population using random digit dialing and tested for the presence of SARS-CoV-2-specific antibodies in the blood serum. Data collection and serial sampling of the same individuals spans four weeks and is conducted every two weeks in order to understand both the spread of the virus in the population.
At least 1 000 individuals, 18 years old and older, are randomly sampled using random digit dialing from the population of Saint Petersburg, Russia. Random sampling is performed by a survey company on the list of mobile phone numbers with designated geography prefixes of St. Petersburg. The baseline questionnaire for computer-assisted telephone interview includes travel history, medical history, and socio-economic status of the respondents. Sampled individuals are then invited to the clinic for blood sampling, their refusal to participate is recorded. Collected blood samples are used for SARS-CoV-2-specific antibodies testing. Data and sample collection spans four weeks and is conducted every two weeks. Participants complete additional questionnaires in the clinic providing information on medical history, history of allergies, chronic disease, smoking, and medication taken regularly. Contact tracing data and environmental conditions of the household are reсorded.
Study Type
OBSERVATIONAL
Enrollment
1,038
Clinic "Scandinavia"
Saint Petersburg, Russia
Prevalence of the SARS-COV-2 infection in Saint Petersburg, Russia
Measured by SARS-CoV-2-specific antibodies serial testing and corrected for volunteer bias and test characteristics.
Time frame: Measured with two-week (14 days) intervals
Prevalence odds ratios
Comparison of prevalence by age, sex and socioeconomic strata.
Time frame: Measured with two-week (14 days) intervals
Immune response dynamics
Seropositivity, seroreversion and seroconversion.
Time frame: Measured with two-week (14 days) intervals
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.